Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022.
Laura Alejandra Torres CanchalaDaniela Cleves-LunaOriana Arias-ValderramaEstephania CandeloMaría Angelica GuerraHarry PachajoaManuela OlayaPublished in: Children (Basel, Switzerland) (2022)
SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.